SCHEMBL514817

SCHEMBL514817

CCOCO[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26622135 0.95
SCHEMBL21634050 0.87 ALDH1A1 (0.39)
SCHEMBL11907827 0.83 ALDH1A1 (0.33)
SCHEMBL514888 0.78
SCHEMBL4398811 0.74
SCHEMBL225859 0.74
SCHEMBL4504039 0.74 CYP3A4 (0.31)
SCHEMBL513839 0.74
SCHEMBL26622165 0.74 HSD17B10 (0.30)
SCHEMBL2897 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005105777-A1 SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA & UPJOHN COMPANY LLC (US) 2005-11-10 WO claimed
EP-0205022-B1 1-ARYL-5-ALKOXIMINOALKYL AMINO PYRAZOLES BAYER AG (DE) 1990-01-10 EP claimed
EP-0216165-A1 Benzodipyrroles, processes for their preparation and pharmaceutical compositions containing these compounds Roche Diagnostics GmbH (DE) 1987-04-01 EP claimed
US-12023338-B2 Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities KYOTO UNIVERSITY (JP) 2024-07-02 US disclosed
EP-4387954-A1 LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL President and Fellows of Harvard College (US) 2024-06-26 EP disclosed
WO-2024128238-A1 THERAPEUTIC AGENT FOR BACTERIAL INFECTION 住友ファーマ株式会社 2024-06-20 WO disclosed
CN-112135830-B Oxo-substituted compounds 住友制药株式会社 2024-06-14 CN disclosed
US-20240165267-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2024-05-23 US disclosed
US-11987590-B2 Compounds that participate in cooperative binding and uses thereof Revolution Medicines, Inc. (US) 2024-05-21 US disclosed
WO-2024096066-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE 第一工業製薬株式会社 2024-05-10 WO disclosed
WO-2024096067-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN 第一工業製薬株式会社 2024-05-10 WO disclosed
US-4406889-A IMMUNOLOGY, PEPTIDES CIBA-GEIGY CORPORATION (US) 1983-09-27 US disclosed
US-4406905-A COMPLEXING, ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1983-09-27 US disclosed
EP-0078002-A2 Herbicides containing triazolo(2,3-b)quinazolone as active ingredient, and their use as plant growth regulators BASF Aktiengesellschaft (DE) 1983-05-04 EP disclosed
EP-0078003-A2 Thiazolo (2,3-b)-quinazolones and process for their preparation BASF Aktiengesellschaft (DE) 1983-05-04 EP disclosed
EP-0045281-A1 Triazoline derivatives and processes for their preparation CIBA-GEIGY AG (CH) 1982-02-03 EP disclosed
US-4313945-A 7-Thiazolyl-acetamido-cephem derivatives with terminal aminocarboxylic acid grouping CIBA-GEIGY CORPORATION (US) 1982-02-02 US disclosed
US-4214094-A ANTILIPEMIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-07-22 US disclosed
US-4145363-A ANTIASTHMATICS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1979-03-20 US disclosed
US-4063025-A PROPHYLAXIS, ANTIASTHMATIC YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) 1977-12-13 US disclosed